Product Introduction

This product is a recombinant virus obtained through reverse genetics by introducing the EGFP gene between the P and M genes of the La Sota strain of Newcastle disease virus (NDV) genome. NDV offers several advantages such as an oncolytic virus:

1) High Safety Profile: NDV is an avian virus with very low pathogenicity to humans, and it is difficult for normal cells to become infected, thus reducing the risk of systemic toxicity. It preferentially replicates within tumor cells (due to tumor cells lacking antiviral interferon pathways), while normal cells can clear the virus through interferon defense, minimizing damage to healthy tissues.

2) Clear Receptor Targeting: NDV infects tumor cells by recognizing highly expressed sialic acid receptors (e.g., gangliosides), which are less abundant on normal cells.

3) Strong Genetic Engineering Potential: NDV can serve as a vector, allowing the insertion of therapeutic genes (e.g., IL-2, GM-CSF, PD-1 inhibitors) into its viral genome to enhance immune activation or directly kill tumors.

Product Application

1) Titer test of serum neutralizing antibodies against NDV La Sota strain;

2) Titer detection of monoclonal antibody against NDV La Sota strain;

3) It can be used for screening oncolytic virus vectors, for screening indications and for tumor-killing purposes, etc.

Example of product infection activity testing